News

Sorin Group announced today a $20 million minority investment in Respicardia, a developer of implantable therapies to improve Respiratory Rhythm Management. Under the terms of the transaction,...

The Cardiovascular Cell Therapy Research Network (CCTRN) has selected Cytori Therapeutics Inc. to supply adipose-derived regenerative cells (ADRC) for a clinical trial aimed at...

Sunshine Heart Inc. today announced the results of its feasibility study entitled “Ambulatory Extra-Aortic Counterpulsation in Patients with Moderate to Severe Chronic Heart Failure,”...

October 15, 2014 — Novartis Pharmaceuticals Canada Inc. revealed, in the largest heart failure study to date, that its investigational heart failure medicine, LCZ696, was superior to the ACE-...

Healthline today launched its HealthData Engine to harness the power of structured and unstructured data to improve outcomes and reduce costs. The new big-data analytics platform...

In partnership with Intel-GE Care Innovations, Cigna-HealthSpring is expanding its population health program that utilizes interactive tablets – the Intel-GE Care Innovations Guide – and...

Researchers have discovered a previously unknown cardiac molecule that could provide a key to treating and preventing heart failure...

LoneStar Heart Inc.Algisyl-LVR Hydrogel Implant Heart Failure Treatment CE Mark

LoneStar Heart Inc. announced that it received the CE mark (Conformite Europeene) for its Algisyl-LVR hydrogel implant, the company's lead product for the treatment of advanced heart failure (HF...

CardiacAssist Inc. announced that the first Protek Duo veno-venous extracorporeal life support (VV ECLS) kit was utilized Sept. 24, at Memorial Hermann Hospital in Houston.

October 8, 2014 — New updates to the Society for Cardiovascular Angiography and Interventions (SCAI) appropriate use criteria (AUC) calculator tool will help healthcare providers in making...

Clinical trial results by Recover Right revealed a survival rate of 73 percent in the total patient population. Recover Right was an FDA-approved, prospective, multicenter, single arm study...

October 8, 2014 — Miracor Medical Systems announced that results from the prospective multicenter safety and feasibility study, ‘Prepare RAMSES,’ were presented at the annual Transcatheter...

St. Vincent Implant Thoratec Corp. HeartMate III VAD

St. Vincent Heart Center officials announced that the faith-based hospital is the second in the nation to implant the new investigational “heart pump.”

October 1, 2014 — Heart Hospital of Austin is the first facility in Texas to implant a new miniaturized, wireless monitoring sensor to manage heart failure (HF). The CardioMEMS HF system...

heartmate III, tohratec, heart failure, heart failure treatment

Thoratec Corporation announced that it has begun to enroll patients in the HeartMate III U.S. clinical trial. 

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said: “Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly...

Unexpected trips to the hospital are inconvenient and worrisome for anyone, but for congestive heart failure sufferers, they can be all too frequent.

BioControl Medical Enrollment INOVATE-HF Study CardioFit System Heart Failure

BioControl Medical announced that it has reached an important clinical trial milestone, reaching 480 randomized subjects — or 70 percent — of the planned 650 subjects with congestive...

Geneia announced a multi-year, strategic partnership with Covidien to help improve the health of and reduce the costs for chronically ill patients. 

Medtronic AdaptResponse Global Clinical Trial Cardiac Resynchronization Therapy

Medtronic Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes — including patient mortality and hospitalizations — in ...